Saratov JOURNAL of Medical and Scientific Research

Pharmacoepidemiological analysis of the drugs used for secondary prevention of brain infarction on dispensary stage

Year: 2014, volume 10 Issue: №1 Pages: 189-195
Heading: Parmacology Article type: Original article
Authors: Miheyeva N.V., Reshetko O.V., Furman N.V.
Organization: Saratov Institute of Cardiology, Russia, Saratov State Medical University

Aim. The secondary prevention of cerebral infarction on dispensary stage to current clinical guidelines was analyzed. Adherence of patients to prescribe medications was evaluated. Material and methods. 106 patients of hospital neurologic department with brain infarction were included in prospective pharmacoepidemiological study of the drugs used for secondary prevention of brain infarction on dispensary stage since 1 January 2009 to 31 December 2009. Duration of outpatient observation was 3 years. Results. All of the patients were of 64,9 ± 10,3 years old. Hypertension was diagnosed in 102 of them (96.2%), atrial fibrillation — in 33 (31.1%) patients. 39 (36.8%) patients died during 3 years after discharge from the hospital. ACE inhibitors/angiotensin II receptor antagonist were prescribed for 83 (78.3%) patients, antiplatelet- 76 (71,7%), statins — 16 (15,1%) patients in discharge from hospital. Warfarin was prescribed only for 1 (3.05%) patient with atrial fibrillation and ischemic stroke.consumption of drugs with evidence efficiency were diminished already after one year of observation in outpatient clinics. Conclusion.Therapy for secondary stroke prevention is not fully comply with current clinical guidelines


1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics — 2013 update: a report from the American Heart Association. Circulation 2013; 27 (1): e6-e245; 2. Gusev El, Skvortsova VI, Stakhovskaya LV. Epidemiology of stroke in Russia. Neurology and psychiatry. Stroke 2003; 8: 4-9; 3. Gusev El, Shimrigk G, Haas N. Results of three years follow-up of patients with ischemic stroke (based on the data bank for stroke). Journal of Neurology 2002; 5:10-14; 4. Boqueria LA, Stupakov IN, Gudkova RG. Successes and problems of the Russian heart surgery. Health 2012; 3: 24-33; 5. Vilensky BS. Strokeprevention, diagnosisandtreatment. St. Petersburg: Foliant, 2002; p. 336-337; 6. Vorlou ChP, Dennis MS, van Gein J, et al. Stroke: A Practical Guide for the management of patients. St. Petersburg: Politekhnika, 1998; 629 p.; 7. Damulin IV, Parfenov VA, Skoromets AA, et. al. Poor circulation in the brain and spinal cord. In: Diseasesofthenervoussystem: a guide for physicians. Moscow: Medicine, 2005. Vol. 1; p. 231-302; 8. Parfenov VA. Antiplatelet agentsin thetreatment and secondaryprevention of ischemicstroke. Nevrology and psychiatry 2007; 10: 812-817; 9. Suslina ZA, Piradov MA. Stroke: diagnosis, treatment and prevention. Moscow: MED presslnform, 2008; 288 p.; 10. Suslina ZA, Tanashyan MM, lonov VG. Ischemic stroke, blood, vascularwall, antithrombotictherapy. Moscow: MedicalBook, 2005; 248 p.; 11. Feigin V, Vibers D, Brown R. Stroke: A clinical guide. Moscow: Binom; St. Petersburg: Dialect, 2005; 608 p.; 12. Skvortsov VI, Chazova IE, Stakhovskaya LV. Secondary stroke prevention. Moscow: PAGRI, 2002; 120 p.; 13. Guide lines for managemen tof ischaemic stroke and transient ischaemic attack 2008. Cerebrovascular Diseases 2008; 25 (5): 457-507; 14. Fonyakin AV, Geraskina LA, Shandalin VA. Prevention of cardiovascularcomplications after stroke: standards, realityand prospects. Neurology, neuropsychiatry, psychosomatics 2010; 1: 24-29; 15. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378 (9798): 1231-1243; 16. Shandalin VA, Fonyakin AV, GeraskinaLA. Secondary preventionof ischemic stroke: from recommendations-toreal clinical practice. Neurology, neuropsychiatry Psychosomatics2012; 2: 35-41; 17. Saposnik G, Goodman SG, Leiter LA. et. al. Applying the evidence: do patients withst roke, coronaryartery disease, or bothachieve similar treatment goals? Stroke 2009; 40:1417-1424; 18. World Health Organisation: adherence to longterm therapies, evidence for action. Geneva: WHO, 2003; 19. Simpson DT, Eurich SR, Majumdar RS, et al. A meta-analysis of the association between adherence to drug therapy and mortality. British Medical Journal 2006; 333: 15; 20. Osterberg L, Blaschke T. Adherence to medication. The New England Journal of Medicine 2005; 353: 487-497; 21. Parfenov VA. Secondary preventionof ischemic stroke. Russian Journal of Medicine2005; 12:819-823; 22. Parfenov VA. Prevention of ischemic strokere-optimization of antiplatelet therapy. Russian Journal of Medicine 2009; 20: 361-365; 23. Gusev El, Boiko AN, Sidorenko TV, et al. Commitment and other primary therapy in patients with post-stroke depression. Journal of Neurology 2011; 16 (4): 54-59; 24. Vasilevska OV, Safina DD, Silantieva IV Causes of inefficiency secondary prevention of ischemic insulta. Kazansky Medical Journal 2012; 93 (5): 744-748; 25. Boytsov SA, Martsevich SJ, et al. Lubertsy mortality study of patients after stroke or transient ischemic attack (LIS-2). Design and evaluation of drug therapy. Rational Pharmacotherapy in Cardiology 2013; 9 (2): 114-122; 26. Petrov VI. Applied pharmacoepidemiology. Moscow: GEOTAR-Media, 2008; 384 p.; 27. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovascular Diseases 2008; 25 (5): 457-507; 28. Gusev El, Konovalov AN, Skvortsova VI, et al. Neurology: national leadership. Moscow: GEOTAR-Media, 2009; 1112 p.; 29. Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment. Cochrane Database of Systematic Reviews 2001; 2. Art. No.: CD001011; 30. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association / American Stroke Association. Stroke 2013; 44: 870-947; 31. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378 (9798): 1231-1243; 32. Dohoung Kim, Seung-Hoon, Lee et al. Secondary prevention by stroke subtype: a nationwide follow-up study in 46108 patients after acute ischaemic stroke. European Heart Journal 2013; doi: 10.1093/eurheartj/eht185; 33. Ostrovsky VO. Evaluationclinical practice: patients with acutecerebral ischemia. Herbal Gazette 2012, 6 (46): 31-38; 34. Alfimova GY, Maslov NN. Register stroke in the Smolensk region. In: Materials 5th Interregional Scientific and Practical Conference "Actual issues of Neurology". Bulletin of Siberian Medicine 2008; 5: 19-23; 35. Chichanovskaya LV. Epidemiology of cerebral stroke in the Tver region. In: Proceedings of the international conference "Topical issues of public health policy". Tver, 2002; p. 25-28; 36. Kachemaeva OB, Borisova NA. Epidemiological characteristics of stroke in Ufa, according to the register. Neurological herald them Bekhterev 2007; 39 (1): 45-48; 37. Diagnosis and treatment of atrial fibrillation: recommendations RKO VNOA and ASSKH, 2012. Moscow: 2012; 38. Camm AJ, Kirchhof Р, Lip GYH, et al. Guidelines for themanagementofatrialfibrillation: the Task Forceforthe Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal 2010; 31 (19): 2369-2429; 39. Suslin ZA, Varakin YY. Epidemiological aspects of studying stroke. Timeto sum up. Anal Clinical and Experimental Neurology 2007; 1 (2): 22-28; 40. Chuchalin AG, Belousov YB, Yasnetsov VV Federal guidelines on the use ofdrugs (formulary system). Moscow: Echoes 2009; X:944 p.; 41. De Deyn PP. et al. Treatment of Acute Ischemic Stroke Wth Piracetam. Stroke 1997; 28: 2347-2352; 42. Ratmanova A. Ischemic stroke and neuroprotection: the search continues. Medicine Review 2008; 3 (03): 38-44; 43. Recommendations for Imaging of Acute Ischemic Stroke: A Scientific Statement From the American Heart Association. Stroke 2009; 40: 3646-3678; 44. Adams H, Adams R, Del Zoppo G, Goldstein LB. Stroke Council of the American Heart Association; American Stroke Association. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association. Stroke 2005; 36 (4): 916-923; 45. European Stroke Initiative (EUSI) Recommendations for Stroke Management: Update 2003. Cerebrovascular Diseases 2003; 16:311-337; 46. Parfenov VA. Risk factors forischemic stroke andsec-ondaryprevention. Neurology, neuropsychiatry. Psychosomatics 2010; 3: 40-45; 47. Zateyschikov DA, Isayev MJ. Questions organization anticoagulation. Clinical Practice 2012; 3: 51-62.

2014_01-01_189-195.pdf484.69 KB

No votes yet